ARTICLE | Clinical News
ThermoDox: Ph III OPTIMA ongoing
December 7, 2016 10:27 PM UTC
Celsion said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase III OPTIMA Study comparing 50 mg/m² IV ThermoDox plus optimized radiofrequency ablation (RFA)...
BCIQ Target Profiles